

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49663 A2

(51) International Patent Classification⁷: C07D

(74) Agents: BUYAN, Robert, D. et al.; Stout, Uxa, Buyan & Mullins, LLP, 4 Venture #300, Irvine, CA 92618 (US).

(21) International Application Number: PCT/US01/00326

(22) International Filing Date: 5 January 2001 (05.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/479,391 6 January 2000 (06.01.2000) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; Office of Technology Transfer, 12th Floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors: **CHANDY, K., George**; 2118 Morningside Drive, Laguna Beach, CA 92651 (US). **WULFF, Heike**; 4109 Palo Verde Road, Irvine, CA 92612 (US). **CAHALAN, Michael, D.**; 2903 Mountain View Drive, Laguna Beach, CA 92651 (US). **GRISMER, Stephan**; Nelly Sachs Str. 4, 89134 Blaustein (DE). **RAUER, Heiko, J.**; 24 Gabrielino Drive, Irvine, CA 92612 (US). **MILLER, Mark, J.**; 127 Dalewood Place, Brea, CA 92821 (US).

Published:

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/49663 A2

(54) Title: NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO

(57) Abstract: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K⁺ channel (IKCa1) in Lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca²⁺ activated K⁺ channel (IKCa1) prevents the pre-Ca²⁺ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO

FIELD OF THE INVENTION

5 This invention relates generally to chemical compositions, preparations and methods for medical treatment and more particularly to the use of certain substituted triarylmethane compounds for immunosuppressive treatment of autoimmune disorders or inflammatory diseases, or the treatment or prevention of transplant rejection or graft-versus-host disease in mammalian patients.

10

BACKGROUND OF THE INVENTION

Organ transplantation has become routine in many parts of the world. Transplants of liver, kidney, heart, lung and pancreas, are now regularly performed as treatment for end-stage organ disease. The outcomes of organ
15 transplant procedures have progressively improved with the development of refinements in tissue typing, surgical techniques, and more effective immunosuppressive treatments. However, rejection of transplanted organs remains a major problem. T-lymphocytes play a central role in the immune response and they are responsible, in large measure, for the rejection of many
20 transplanted organs. They are also responsible for the so-called graft-versus host disease in which transplanted bone marrow cells recognize and destroy MHC-mismatched host tissues. Accordingly, drugs such as cyclosporin and FK506 that suppress T-cell immunity are used to prevent transplant rejection and graft-versus-host disease. Unfortunately, these T-cell inhibiting drugs are toxic,
25 with liver and renal toxicities limiting their use.

Autoimmune diseases encompass a whole spectrum of clinical disorders wherein a patient's immune system mistakenly attacks self, targeting the cells, tissues, and organs of the patient's own body. The following are some examples of autoimmune diseases, categorized with respect to the target organ that is
30 principally affected by each such disease:

Nervous System:

Multiple sclerosis
Myasthenia gravis
Autoimmune neuropathies
such as Guillain-Barré
Autoimmune uveitis

Blood:

Autoimmune hemolytic anemia
Pernicious anemia
Autoimmune thrombocytopenia

Vascular:

Temporal arteritis
Anti-phospholipid syndrome
Vasculitides such as
Wegener's granulomatosis
Behcet's disease

Skin:

Psoriasis
Dermatitis herpetiformis
Pemphigus vulgaris
Vitiligo

Gastrointestinal Tract:

Crohn's Disease
Ulcerative colitis
Primary biliary cirrhosis
Autoimmune hepatitis

Endocrine:

Type 1 diabetes mellitus
Addison's Disease
Grave's Disease
Hashimoto's thyroiditis
Autoimmune oophoritis and
orchitis

**Multiple Organs and/or
Musculoskeletal System:**

Rheumatoid arthritis
Systemic lupus erythematosus
Scleroderma
Polymyositis, dermatomyositis
Spondyloarthropathies such as
ankylosing spondylitis
Sjogren's syndrome

Irrespective of the particular organ(s) affected, T-lymphocytes are believed to contribute to the development of autoimmune diseases. The currently
5 available therapies for these diseases are largely unsatisfactory and typically involve the use of glucocorticoids (e.g. methylprednisolone, prednisone), non-steroidal anti-inflammatory agents, gold salts, methotrexate, antimalarials, and other immunosuppressants such as cyclosporin and FK-506.

Thus, the search for additional immunosuppressive agents for preventing
10 transplant rejection and for the treatment of autoimmune and inflammatory disorders occupies considerable attention in the pharmaceutical industry. Since cytokines such as interferon-gamma and tumor necrosis factor-alpha play a critical role in transplant rejection and in the pathophysiology of autoimmune disorders, much effort has been invested in the development of agents that
15 suppress their production, secretion and/or end-organ effect.

There is an excellent track record of treating nervous and cardiovascular disorders with ion channel modulators – either openers or blockers. Ion channel blockers as a general class, represent the major therapeutic agents for treatment of stroke, epilepsy and arrhythmias. Since ion channels play a major role in the T-cell immune response, these channels may represent attractive targets for pharmaceutical immunomodulation.

The early stages of T-cell activation may be conceptually separated into pre- Ca^{++} and post- Ca^{++} events (Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749). Following engagement of antigen with the T-cell antigen-receptor, activation of tyrosine kinases and the generation of inositol 1,4,5-triphosphate leads to the influx of Ca^{++} through store-operated calcium channels (also known as Calcium-Release Activated Calcium or CRAC channels) and the rise of cytoplasmic Ca^{2+} concentration (Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749; Kerschbaum and Cahalan 1999, *Science* 283: 836; Kerschbaum and Cahalan 1998; *J. Gen. Physiol.* 111: 521). The rise in Ca^{++} activates the phosphatase calcineurin, which then dephosphorylates a cytoplasmically localized transcription factor (N-FAT) enabling it to accumulate in the nucleus and bind to a promoter element of the interleukin-2 gene. Along with parallel events involving the activation of protein kinase C and ras, gene transcription leads to lymphokine secretion and to lymphocyte proliferation. Some genes require long-lasting Ca^{++} signals while others require only a transient rise of Ca^{++} . Furthermore, Ca^{++} immobilization of the T-cell at the site of antigen presentation helps to cement the interaction between T-cell and the antigen-presenting cell and thereby facilitate local signaling between the cells (Negulescu 1996, *Immunity* 4:421).

Ion channels underlie the Ca^{++} signal of T-lymphocytes. Ca^{++} ions move across the plasma membrane through a channel termed the store-operated Ca^{++} channel or the CRAC channel which is activated by depletion of internal calcium stores like the endoplasmic reticulum (Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749). Two distinct types of potassium channels indirectly determine the driving force of calcium entry through the store-operated Ca^{2+} channel (Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749). The first is the voltage-gated *Kv1.3* channel (Cahalan 1985, *J. Physiol.* 385: 197; Grissmer 1990, *Proc. Natl. Acad. Sci. USA* 87: 9411; Verheugen 1995, *J. Gen. Physiol.*

105: 765; Aiyar 1996, *J. Biol. Chem.* 271: 31013; Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749) and the second is the intermediate-conductance calcium-activated potassium channel, *IKCa1* (Grissmer 1993, *J. Gen. Physiol.* 102: 601; Fanger 1999 *J. Biol. Chem.* 274: 5746; Rauer 1999, *J. Biol. Chem.* 274: 21885) which is also known as *IK1* (VanDorpe 1998, *J. Biol. Chem.* 273: 21542), *hSK4* (Joiner 1997, *Proc. Natl. Acad. Sci. USA* 94: 11013; Khanna 1999, *J. Biol. Chem.* 274: 14838) and *hKCa4* (Lodgson 1997, *J. Biol. Chem.* 272: 32723; Ghanshani 1998, *Genomics* 51: 160). When these potassium channels open, the resulting efflux of K^+ hyperpolarizes the membrane, which in turn accentuates the entry of Ca^{++} , which is absolutely required for downstream activation events (Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749). Blockers of the *Kv1.3* and *IKCa1* channels suppress human T-cell activation, when applied independently, and produce greater suppression when applied together (DeCoursey 1984, *Nature* 307: 465; Chandy *J. Exp. Med.* 160: 369; Koo 1997, *J. Immunol.* 158: 5120; Nguyen 1995, *Mol. Pharmacol.* 50: 1672; Hanson 1999, *Br. J. Pharmacol.* 126: 1707; Kalman 1998, *J. Biol. Chem.* 273: 32697; Khanna 1999, *J. Biol. Chem.* 274: 14838; Jensen 1999, *Proc. Natl. Acad. Sci. USA* 96: 10917). One mechanism for the immunosuppression by K^+ channel blockers is via membrane depolarization, which reduces Ca^{++} entry through CRAC channels in the T-cell membrane, which in turn leads to suppression of calcium-dependent signaling events during human T-cell activation (Cahalan and Chandy 1997, *Curr. Opin. Biotechnol.* 8: 749; Koo 1999, *Cell. Immunol.* 197: 99).

Clotrimazole, a non-selective inhibitor of *IKCa1*, suppresses mitogen-stimulated T-cell activation, especially of pre-activated cells (Khanna 1999, *J. Biol. Chem.* 274: 14838; Jensen 1999, *Proc. Natl. Acad. Sci. USA* 96: 10917). Clotrimazole and related imidazoles, other than the compounds of this invention, have also previously been described for use in treating rheumatoid arthritis, an autoimmune disorder (Wojtulewski 1980, *Ann. Rheum. Dis.* 39: 469; Wyburn-Mason 1976, US4073922; Wyburn-Mason 1987, US183941; Wyburn-Mason 1979, US4218449). However, clotrimazole shows considerable toxicity with increasing doses, toxicity being primarily associated with its potent (nanomolar) inhibition of cytochrome P450 enzymes (Wojtulewski 1980, *Ann. Rheum. Dis.* 39: 469; Burgess 1972 *Antimicrob. Agents Chemother.* 2: 423; Brugnara 1996, *J.*

Clin Invest. 97: 1227). Thus, there clearly is a need for newer analogs that block *IKCa1* without concomitant inhibition of cytochrome P450-dependent enzymes.

Other patents have described the use of clotrimazole, related azole antimycotics (e.g., miconazole and econazole) and related aromatic halides for the treatment of cancer (Halperin 1994, WO 96/08240; Halperin 1997 US 5633274), but only at micromolar concentrations (Benzaquen 1995, *Nat. Med.* 1: 534), substantially greater than the concentrations required to block the *IKCa1* channel (~ 20-100 nM), suggesting that the mechanism of suppression of proliferation might be unrelated to channel block. Also at micromolar concentrations, clotrimazole, related azole antimycotics (e.g., miconazole and econazole) and related aromatic halides have been described for use in the treatment of arteriosclerosis as a hyperproliferative disease (Halperin 1994, WO 94/189680 and US 5358959), and for the treatment of diseases characterized by neovascularization (Halperin 1996, US 5512591; Halperin 1997, US 5643936 and US 5591763).

At least some of the triarylmethyl-1*H*-pyrazole compounds of the present invention have also previously been described in PCT International Publication WO 97/34599 entitled *USE OF CLOTRIMAZOLE AND RELATED COMPOUNDS IN THE TREATMENT OF DIARRHEA*, as being useable for the treatment of diarrhea, although they do not constitute preferred embodiments of the inventions.

Also, PCT International Publication WO/97/34589 entitled *TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE* describes various substituted triarylmethane compounds as effective treatments for sickle cell disease due to their ability to inhibit ion flux through the calcium activated potassium channel (Gardos channel) of erythrocytes, which has now been shown to be encoded by the *IKCa1* gene (VanDorpe 1998, *J. Biol. Chem.* 273: 21542). Clotrimazole, the preferred compound in this invention is in phase II trials for the treatment of sickle cell disease gene (VanDorpe 1998, *J. Biol. Chem.* 273: 21542), but at higher doses causes toxic side effects most likely due to its inhibition of cytochrome P450 enzymes. The PCT International Publication WO/97/34589 also describes various substituted triarylmethane compounds as effective treatments for diseases characterized by unwanted or abnormal cell proliferation (the examples cited being melanoma cells and fibroblast

proliferation), but at only micromolar concentrations (Benzaquen 1995, *Nat. Med.* 1: 534; Halperin 1997 US 5633274; PCT application WO/97/34589; PCT application WO/97/08240) which are substantially higher than that required for block of the *IKCa1* channel (half-block at 20-100 nM), suggesting that the
5 mechanism of suppression of cell proliferation might be unrelated to channel block. Furthermore, since the three compounds used to support this claim, clotrimazole, ketoconazole and miconazole (Benzaquen 1995, *Nat. Med.* 1: 534) also inhibit cytochrome P450 enzymes at nanomolar concentrations (Mason 1987, *Steroids* 50: 179; Morris 1992, *FASEB J.* 6: 752), the mechanism of
10 suppression of abnormal proliferation may be related to inhibition of these enzymes. Another possible mechanism for suppression of proliferation stated in PCT application WO/97/34589 is non-specific cytotoxicity. Therefore, the claims in PCT application WO/97/34589 that suppression of abnormal proliferation is due solely to alteration of transmembrane ion fluxes cannot be substantiated.

15 WO 97/34589 does not describe or suggest that the substituted triarylmethane compounds disclosed therein are capable of selectively blocking the calcium activated potassium channels encoded by the *IKCa1* gene in resting and activated T-lymphocytes, or that such compounds would, alone or in combination with other inhibitors of T-cell signaling cascades, suppress antigen-,
20 cytokine- and/or mitogen-stimulated calcium-entry through store-operated calcium channels, and/or cytokine production and/or activation of human T-lymphocytes, without concomitant inhibition of cytochrome P450 enzymes, leading to immunosuppressive activity when administered to mammalian patients.

25 Given the shortcomings associated with the currently available modes of therapy for autoimmune disorders, transplant rejection and graft-versus-host disease, there remains a need for the development of new immunosuppressive drugs that are capable of selectively inhibiting the activation of lymphocytes with minimal side effects, and without affecting the cytochrome P450 enzyme system.


30

SUMMARY OF THE INVENTION

The present invention generally comprises pharmaceutical preparations containing substituted triarylmethane compounds, as listed in Appendix A, and

methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft-versus-host disease by administering therapeutically effective amounts of such compounds to mammalian patients.

In accordance with the invention, there is provided a method for inhibiting antigen-, cytokine-, or mitogen-induced calcium-entry through store-operated calcium channels, cytokine production and cell activation in lymphocytes, monocytes, macrophages and for treating autoimmune disorders, graft rejection and/or graft-versus-host disease by administering to a mammalian patient a therapeutically effective amount of at least one compound having the general structural formula:



Wherein,

X, Y and Z are same or different and are independently selected from CH_2 , O, S, NR_1 , $\text{N}=\text{CH}$, $\text{CH}=\text{N}$ and $\text{R}_2\text{-C}=\text{C-R}_3$, where R_2 and R_3 are H or may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups;


R_1 is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxycarbonyl groups;

R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy, alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxycarbonyl, $\text{N-(R}_4\text{)(R}_5\text{)}$ and saturated or unsaturated, chiral or achiral, cyclic or acyclic, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms, optionally substituted with hydroxy, halogen, trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxycarbonyl, oxoalkyl, cyano and $\text{N-(R}_4\text{)(R}_5\text{)}$ group,

R_4 and R_5 are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R_4 and R_5 may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or N- R_6 ,

R_6 is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl,

n is 0-5; m is 1 or 2; with the proviso that when m is 1, Q is selected from OH, CN, carboxyalkyl, N-(R_7)(R_8), where R_7 and R_8 are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl, amido, or R_7 and R_8 may combine to form a saturated or unsaturated heterocyclic ring and optionally substituted with up to 3 additional heteroatoms selected from N, O, and S; or -NH-heterocycle, where the heterocycle is represented by thiazole, oxazole, isoxazole, pyridine, pyrimidine, and purine and where U and V are selected from H and O; and




when m is 2, Q is a spacer of from 2-10 carbons either as a straight or branched hydrocarbon chain, or containing a hydrocarbon ring such as phenyl.

In the most preferred embodiment of this invention, X, Y, and Z are $R_2-C=C-R_3$, where R_2 and R_3 are H; R is selected from H and halogen, preferably, F and Cl; m is 1; and

Q is -N-(R_7)(R_8), where R_7 and R_8 are selected from H, acyl, amido, and R_7 and R_8 combine to form a saturated or unsaturated heterocyclic ring, optionally substituted with up to three heteroatoms selected from N, O, or S, for example, pyrrolidine, piperidine, pyrazole, oxazole, isoxazole, tetrazole, azepine, etc., which may be optionally substituted with a lower alkyl or amino group.

Further in accordance with the invention, preferred compounds of this invention having the general Formula I above, are a group of triarylmethyl-1H-pyrazole compounds that have structural Formula I-A below:



Formula 1-A

Wherein:

X, Y, and Z are $R_2-C=C-R_3$, where R_2 and R_3 are H;
R is selected from H and halogen, preferably, F and Cl;

5

Compounds of Formula I-A have been determined to selectively inhibit the intermediate-conductance calcium-activated potassium channel, *IKCa1*, at low nanomolar concentrations, and exhibit 200-1500 fold selectivity for this channel over other ion channels, and over cytochrome P450-dependent enzymes.

10

Still further in accordance with the invention, 1-[(2-chlorophenyl)diphenyl methyl]-1*H*-pyrazole (designated as T34 in Appendix A) and possibly other compounds of Formulas I and I-A above, when administered to mammalian patients, inhibit (i.e., block or partially block) the intermediate conductance Ca^{++} activated K channel (*IKCa1*) expressed in resting and activated lymphocytes, 15 monocytes, macrophages, platelets and endothelial cells. By inhibiting the *IKCa1* channel in lymphocytes, monocytes, macrophages, platelets and endothelial cells the present invention prevents or deters Ca^{++} entry and, thus, disrupts the signaling cascade that leads to cytokine production and cell activation. It is by this mechanism, and possibly others, that the compounds of Formulas I and I-A 20 are useable to cause suppression of immune and anti-inflammatory responses. Unlike clotrimazole, the compounds of Formula I and I-A lack the imidazole moiety that is believed to be responsible for inhibition of cytochrome P450-dependent enzymes and, thus, the compounds of Formula II above will inhibit or block the Ca^{++} activated K^+ channel (*IKCa1*) without also causing inhibition of 25 cytochrome P450-dependent enzymes. In this manner, the compounds of Formula I and I-A can be administered in amounts that are effective to inhibit (i.e., block or partially block) the Ca^{++} activated K^+ channel (*IKCa1*) without causing at least some of the toxic side-effects associated with cytochrome P450 inhibition by clotrimazole.

30

BRIEF DESCRIPTION OF THE DRAWINGS

FIGURE 1a shows the block of an *IKCa1* current (*hIKCa1* expressed in COS-7 cells) by 100 nM T34.

FIGURE 1b shows the Hill plot ($nH = 1.8$) of the reduction of slope conductance at -80 mV of *IKCa1* currents in COS-7 cells ($n = 15$).

FIGURE 1c is a graph showing the effect of 100 nM of T34 on native *IKCa* currents in a human T-lymphocyte after 4 days of activation with 1 μ g/ml PHA.

5 Currents were elicited by 200 ms voltage ramps from -160 to 40 mV every 30 s with 1 μ M of free Ca^{++} in the pipette solution.

FIGURE 2 shows the hydrolysis of compound T34 and clotrimazole at pH 7.4 and pH 5.0.

FIGURE 3 shows the hydrolysis of compound T34 to T3 at pH1.

10

DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS OF THE INVENTION

The following detailed description, and the examples contained therein, are provided for the purpose of describing and illustrating certain embodiments of the invention only and are not intended to limit the scope of the invention in any way.

The present invention provides for the use of therapeutically effective substituted triaryl methane compounds that are more selective in inhibiting the said channel in nanomolar concentrations and exhibiting no inhibitory effect on the cytochrome P450-dependent enzyme systems at 50 times greater concentrations. Because the imidazole moiety is responsible for inhibition of cytochrome P-450-dependent enzymes, applicants have synthesized compounds of Formula I and I-A above that do not include the imidazole moiety, including instead other heterocyclic groups. Applicants have also synthesized a range of triaryl-methanols, amines, ureas, acetonitriles and related compounds, as listed in Appendix A, by synthetic methodologies outlined in Scheme 1 below. The triarylmethyl-1-*H*-pyrazoles of this invention potently block *IKCa1*. Applicants have further discovered that one particular compound of this invention having

20 Structural formula I-B below, exhibits ~3-fold greater affinity for the channel ($K_d = 20$ nM) than clotrimazole ($K_d = 70$ nM), and does not inhibit cytochrome P450 3A4, the major xenobiotic metabolizing enzyme in the human liver, even at a concentration of 10 μ M. Four other compounds in this series (T39, T40, T46 and T84) are more potent inhibitors of *IKCa1* channels than clotrimazole (TABLE 8).

30

Furthermore, applicants have discovered that the ratio of cytochrome P-450-dependent enzyme systems inhibition (EC_{50}) to *IKCa1* inhibition (K_d) needs to be >50-100 to achieve the therapeutic effect for prevention of the diseases modulated by *IKCa1* channel without the aforementioned side effects evident in
5 clotrimazole and related imidazoles.

As a further test of selectivity, applicants have evaluated 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole, one of the compounds of this invention (designated as T-34 in Appendix A), on other cloned and native ion channels, (*Kv1.1-1.5*, *Kv3.1*, *Kv4.2*, Jurkat-SK_{Ca}, BKCa, *hSKM1*-Na, CRAC and
10 lymphocyte chloride channels). All of these channels were blocked with K_d values ~ 5 μ M. Thus, T34 was found to be a remarkably potent and selective *IKCa1* inhibitor. Because of its structural similarity to clotrimazole and based on experimental data described in the examples below, we expect that T34 ($\log P$ = 4.0 versus 3.5 for clotrimazole) will have a similar or slightly better bioavailability
15 than clotrimazole and, contrary to clotrimazole, no side effects mediated by inhibition of cytochrome P450-dependant enzymes.

The invention is particularly concerned with compounds for effective treatments for auto-immune disorders, transplant rejection, inflammatory disorders and graft-versus-host disease. Accordingly, the present invention
20 provides compositions and methods suitable for treatment of said diseases, and further provides therapy devoid of side effects associated with currently available drugs on the market.

The present invention includes methods that are specifically intended to suppress the immune system and reduce inflammation in a mammalian patient
25 who is in need of such treatment. Specifically, the method of this invention is useful in treating and preventing the resistance to transplantation rejection of organs or tissues (such as heart, kidney, liver, lung, bone marrow, cornea, pancreas, limb, nerves, medulla ossium, duodenum, small bowel, skin, pancreatic islet etc. including xeno transplantation), graft-versus-host diseases,
30 autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, Hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, type I diabetes mellitus, nephrotic syndrome, steroid-dependent and steroid-resistant nephrosis, palmar-plantar pustolosis, allergic encephalomyelitis,

glomerulonephritis, Behcet's syndrome, ankylosing spondylitis, polymyositis, fibromyositis, etc.

The compounds of this invention are also useful for treating inflammatory, proliferative and hyperproliferative skin diseases and cutaneous manifestations of immunologically mediated illnesses such as psoriasis, psoriatic arthritis, atopic dermatitis, contact dermatitis and other eczematous dermatitises, seborrheic dermatitis, Lichen planus, Pemphigus, bullous Pemphigus, Epidermolysis bullosa, angiodemas, vasculitides, erythemas, cutaneous eosinophilias, acne, Alopecia areata, and arteriosclerosis.


10 The compounds of the invention are further useful in the treatment of respiratory diseases, for example sarcoidosis, fibroid lung, idiopathic interstitial pneumonia, and reversible obstructive airway diseases, including conditions such as asthma, including bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma and dust asthma, bronchitis and the like. The compounds may also be
15 useful for the treating hepatic injury associated with ischemia.

The compounds may also be indicated in certain eye diseases such as keratoconjunctivitis, vernal conjunctivitis, keratitis, uveitis, corneal leukoma, ocular pemphigus, Mooren's ulcer, Scleritis, Graves' ophtalmopathy, sympathetic ophthalmia and the like.

20 The compounds are also useful treating inflammatory bowl diseases (e.g. Crohn's disease), neurological diseases (including Guillain-Barre syndrome, Meniere's disease, radiculopathy), endocrine diseases (including hyperthyroidism and Basedow's disease), hematological diseases (including pure red cell aplasia, aplastic anemia, hypoplastic anemia, idiopathic thrombocytopenic purpura,
25 autoimmune hemolytic anemia, agranulocytosis and anerythroplasia), bone diseases (including osteoporosis), respiratory disease (including sarcoidosis, idiopathic interstitial pneumonia), skin diseases (including dermatomyositis, leukoderma vulgaris, ichthyosis vulgaris, photoallergic sensitivity and cutaneous T cell lymphoma), genitals (orchitis, vulvitis), circulatory diseases (including
30 arteriosclerosis, polyarteritis nodosa, vasculitis, Buerger's disease, and myocardosis), collagen disorders (including scleroderma, aortitis syndrome, eosinophilic fascitis, Wegener's granulomatosis, Sjogren's syndrome, periodontal diseases), kidney diseases (including nephrotic syndrome, hemolytic-uremic syndrome, Goodpasture's syndrome) and muscular dystrophy. The compounds

may also be useful for the treatment of diseases including intestinal inflammations/allergies such as Coeliac disease, proctitis, ulcerative colitis, eosinophilic gastroenteritis, mastocytosis, Crohn's disease and ulcerative colitis and food-related allergic diseases which have symptomatic manifestations remote from the gastrointestinal tract, for example migraine, rhinitis and eczema. Further, the invention can be used for treating preventing or treating inflammation of mucosa or blood vessels (such as leukotriene-mediated diseases), gastric ulcers, vascular damage caused by ischemic diseases and thrombosis, ischemic bowl diseases. Further, the invention will be useful for treating multidrug resistance of tumor cells, (i.e. enhancing the activity and/or sensitivity of chemotherapeutic agents).

The compounds may be useful for the treatment and prevention of hepatic diseases such as immunogenic diseases (e. g. chronic autoimmune liver diseases including autoimmune hepatitis, primary biliary cirrhosis and sclerosing cholangitis), partial liver resection, acute liver necrosis (e.g. necrosis caused by toxins, viral hepatitis, shock or anoxia), B-virus hepatitis, nonA/nonB hepatitis, cirrhosis.



Formula I

A. Compounds Useable In Accordance With This Invention:

As stated in the above-set-forth summary of the invention, the compounds of this invention are represented by Formula I below,

Wherein,

X, Y and Z are same or different and are independently selected from CH₂, O, S, NR₁, N=CH, CH=N and R₂-C=C-R₃, where R₂ and R₃ are H or may

combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups;

R₁ is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxycarbonyl groups;

R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy, alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxycarbonyl, N-(R₄)(R₅) and saturated or unsaturated, chiral or achiral, cyclic or acyclic, straight or branched hydrocarbonyl group with from 1 to 20 carbon atoms, optionally substituted with hydroxy, halogen, trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxycarbonyl, oxoalkyl, cyano and N-(R₄)(R₅) group,


R₄ and R₅ are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R₄ and R₅ may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or N-R₆,

R₆ is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl,

n is 0-5; m is 1 or 2; with the proviso that when m is 1, Q is selected from OH, CN, carboxyalkyl, N-(R₇)(R₈), where R₇ and R₈ are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl, amido, or R₇ and R₈ may combine to form a saturated or unsaturated heterocyclic ring and optionally substituted with up to 3 additional heteroatoms selected from N, O, and S; or

-NH-heterocycle, where the heterocycle is represented by thiazole, oxazole, isoxazole, pyridine, pyrimidine, and purine and

where U and V are selected from H and O; and



when m is 2, Q is a spacer of from 2-10 carbons either as a straight or branched, chiral or achiral, cyclic or acyclic hydrocarbon group, such as phenyl.

In the most preferred embodiment of this invention,
X, Y, and Z are $R_2-C=C-R_3$, where R_2 and R_3 are H;
R is selected from H and halogen, preferably, F and
Cl;

m is 1; and

Q is $-N-(R_7)(R_8)$, where R_7 and R_8 are selected from
H, acyl, amido, and R_7 and R_8 combine to form a
saturated or unsaturated heterocyclic ring, optionally
substituted with up to three heteroatoms selected from
N, O, or S, for example, pyrrolidine, piperidine,
pyrazole, oxazole, isoxazole, tetrazole, azepine, etc.,
which may be optionally substituted with a lower alkyl
or amino group.

Some of the preferred compounds covered by Formula I include,

(2-chlorophenyl)diphenyl methanol (T3)

(2-thienyl)diphenyl methanol (T9)

N-[(2-chlorophenyl)diphenylmethyl]-urea (T33)

1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrrole (T44)

N-[(2-chlorophenyl)diphenylmethyl]-*N*-(2-pyrimidyl)amine (T68)

(2-chlorophenyl)diphenylmethyl amine (T41)

N-(2-chlorophenyl)diphenylmethyl acetamide (T75)

2-(4-chlorophenyl)-2,2-diphenylacetonitrile (T26)

2-(2-chlorophenyl)-2,2-diphenylacetonitrile (T39)

2-[(2-chlorophenyl)(diphenyl)methyl]-1*H*-isoindole-1,3(2*H*)-dione
(T71)

1-[(2-chlorophenyl)diphenylmethyl]-1*H*-tetrazole (T84).

In another preferred embodiment having the general Formula I X, Y, and Z
are each $R_2-C=C-R_3$ (where R_2 and R_3 are H;

R is selected from H and halogen, preferably, F and Cl); m is 2; and


Q is a spacer of from 2-10 carbons either as a straight or branched hydrocarbon
chain, or containing a hydrocarbon ring such as phenyl. Some of the preferred
compounds covered by this embodiment include:

N,N-1,2-ditritylamino ethane (T21)

1,4-ditritylaminomethyl benzene (T23)

N,N-1,3-[(2-chlorophenyl)diphenylmethyl] amino propane (T49).

Further in accordance with the invention, preferred compounds of this invention having the general Formula I above, are a group of triarylmethyl-1*H*-pyrazole compounds that have structural Formula I-A below:

**Formula 1-A**

5 Wherein:

X, Y, and Z are R₂-C=C-R₃, where R₂ and R₃ are H;
R is selected from H and halogen, preferably, F and Cl;

10 Preferred compounds covered by Formula I-A include,

1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T34)

1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole (T46)


1-[(4-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T13)

15 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole (T28)

B. Synthesis of the Compounds:

The compounds of this invention may be prepared as outlined in Scheme 1 and

20 Example 1. The individual steps are described below in the examples. The synthetic procedures described here are exemplary and may be modified by those skilled in the art .



Scheme 1. Synthesis of triarylmethanes

C. Preferred Routes of Administration:

The compounds described herein, or pharmaceutically acceptable salts or hydrates thereof, can be delivered to a patient using a wide variety of routes or modes of administration. Suitable routes of administration include, but are not limited to, inhalation, transdermal, oral, rectal, transmucosal, intestinal and parenteral administration, including intramuscular, subcutaneous and intravenous injections.

The compounds described herein, or pharmaceutically acceptable salts or hydrates thereof, may be administered singly or in combination with other therapeutic agents, e.g. analgesics, antibiotics, non-steroidal anti-inflammatory agents, steroids, and other immunosuppressive drugs like cyclosporin A, rapamycin, FK506 or Kv1.3 selective blockers. At least one of the preferred compounds, 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole designated as T34

in Appendix A, may be administered *per se* or in the form of a pharmaceutical composition wherein the active compound is in admixture with one or more physiologically acceptable carriers, excipients or diluents. Pharmaceutical compositions for use in accordance with the present invention may be formulated

5 in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries, which facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen. For parenteral administration (bolus injection or continuous infusion), the agents of the invention

10 may be formulated in water-soluble form in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. Additionally, suspensions of the compounds may be prepared as oily injections with fatty oils, synthetic fatty acid esters, or liposomes. The compounds may also be formulated as a depot preparation. For oral

15 administration, the compounds can be formulated readily by combining the active compound with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion for patients to be treated. Suitable excipients are, in particular,

20 fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example maize starch, wheat starch, rice strach, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl-methylcellulose, sodium carboxymethylcellulose, and/ or polyvinylpyrrolidone.

C. Examples:

25 The following examples serve to illustrate various aspects of the invention and are not to be construed as limiting the invention to those embodiments so exemplified.

Example 1

30 **Synthesis of Triarylmethanols (General Method A)**

25 mmol of magnesium turnings and a catalytic amount of iodine to initiate the reaction were stirred in 50 ml of anhydrous diethyl ether. Then, a solution containing 25 mmol of the appropriate aryl bromide in anhydrous diethyl ether (50

ml) was slowly added allowing a gentle reflux. Once the addition was complete the mixture was heated at reflux until all the magnesium was consumed. Next, a solution of the required benzophenone (25 mmol) in anhydrous diethyl ether (50 ml) was slowly added. The resulting mixture was heated at reflux for 5-12 h, then cooled to 0 °C and poured into 100 ml of cold water. To dissolve the precipitating magnesium hydroxide the mixture was acidified with concentrated HCl. The organic phase was separated, and the aqueous phase was extracted with diethyl ether. The combined organic phases were washed with sodium bicarbonate solution (10%) and then dried over sodium sulfate. Evaporation of the solvent gave the respective triarylmethanol either as creamy solid or as an oil, which normally was recrystallized from petroleum ether (40-60 °C) several times.

Example 2

15 Preparation of (2-Chlorophenyl)diphenyl methanol (Compound T3)

Following the procedure outlined in Example 1, 1.3 g (52 mmol) of magnesium turnings, 10.0 g (52 mmol) of 1-bromo-2-chlorobenzene and 9.4 g (52 mmol) benzophenone gave 9.81 g (64%) of (2-Chlorophenyl) diphenyl methanol (Compound T3), mp: 91 °C.

20

Example 3

Following the procedure outlined in Example 1, the following triarylmethanols (Table 1) were prepared.

25 **Table 1.**

Triarylmethanol Compound	Designation on Appendix A	Yield	Melting Point
(4-Chlorophenyl)diphenyl methanol	T1	56%	82 °C
(3-Chlorophenyl)diphenyl methanol	T2	52%	53 °C
Bis-(4-chlorophenyl)phenyl methanol	T4	56%	86 °C
Bis-(3-chlorophenyl)phenyl methanol	T5	52%	oil
(2-Thienyl)diphenyl methanol	T9	64%	129 °C
(4-Fluorophenyl)diphenyl methanol	T12	58%	120.5 °C
(4-Fluorophenyl)(2-thienyl)phenyl methanol	T14	62%	75 °C
Bis-(4-methoxyphenyl)phenyl methanol	T15	62%	sticky dark red paste
Tris-(4-methoxyphenyl) methanol	T16	48%	75 °C

Di-(2-thienyl)phenyl methanol	T35	54%	86 °C
(2-Fluorophenyl)diphenyl methanol	T36	69%	116 °C
(2-Chlorophenyl)(2-thienyl)phenyl methanol	T43	58%	90.5 °C
Diphenyl(2-trifluoromethylphenyl) methanol	T54	57%	111 °C
Diphenyl(4-trifluoromethylphenyl) methanol	T55	68%	oil
Diphenyl(3-trifluoromethylphenyl) methanol	T56	62%	52 °C

Example 4

5 Synthesis of Triaryl chlorides (General Method B)

To a stirred suspension of 20 mmol of the corresponding triarylmethanol in 100 ml of petroleum ether (40-60 °C) was added dropwise an excess of freshly distilled thionyl chloride. The reaction mixture was stirred at room temperature for 30 min and then heated under reflux for 1h. Excess thionyl chloride was removed
 10 by concentrating to dryness in vacuo. The residue was suspended in 100 ml of petroleum ether and left in the refrigerator overnight. The resulting crystals were filtered off and thoroughly washed with petroleum ether. To avoid hydrolysis of these sensitive triaryl chlorides, they were immediately used for further reactions after being characterized by melting point and mass spectrometry.

15

Example 5

Synthesis of (2-Chlorophenyl)diphenyl chloromethane:

Following the procedure outlined in Example 4, 5.00 g (17.1 mmol) of (2-chlorophenyl) diphenyl methanol, designated as T-3 on Appendix A, was treated
 20 with 2.5 ml thionyl chloride (34 mmol) according to general method B to give 4.39 g (82 %) of (2-Chlorophenyl) diphenyl chloromethane, mp: 131 °C

Example 6

Synthesis of Triarylmethylamines (General Method C):

25 To a solution of the appropriate triaryl chloride (5 mmol) in anhydrous acetonitrile (100 ml) were added the desired amine or urea (5 mmol) and triethylamine (5 mmol) as proton acceptor. The resulting mixture was stirred and heated at reflux for 24 h. Evaporation of the solvent afforded a creamy residue,

which was dissolved in 200 ml of methylene chloride. The mixture was washed two times with 50 ml of water, dried over Na₂SO₄, and concentrated in vacuo. The crude product was recrystallized from petroleum ether (40-60 °C) / methylene chloride.

5

Example 7

Preparation of 1-Tritylpyrrolidine (Compound T7)

2.00 g (7.2 mmol) of trityl chloride was treated with 0.51 g (7.2 mmol) pyrrolidine and 0.72 g (7.2 mmol) triethylamine according to General Method C in

10 Example 6 to give 1.86 g (82 %) of 1-tritylpyrrolidine (T7), mp: 126 °C

Example 8

Following the procedure in Example 6, the following compounds (Table 2) were prepared.

15

Table 2.

Triarylmethylamines from an amine or urea	Number	Yield	Melting Point
1-Trityl-1 <i>H</i> -pyrrole	T10	79%	243 °C
<i>N</i> -trityl urea	T24	58%	238 °C
<i>N</i> -[(4-Chlorophenyl)diphenylmethyl] urea	T29	62%	228 °C
<i>N</i> -[(4-Fluorophenyl)diphenylmethyl] urea	T31	66%	222 °C
<i>N</i> -[(2-Chlorophenyl)diphenylmethyl] urea	T33	68%	243 °C
1[(2-Chlorophenyl)diphenylmethyl]-1 <i>H</i> -pyrrole	T44	67%	184 °C
<i>N</i> -[(2-Fluorophenyl)diphenylmethyl] urea	T45	66%	225 °C

Example 9

20 Synthesis of Triarylmethylamines with a Heterocyclic amine (General Method D)

Especially with substituted pyrazoles and pyrimidines General Method C tended to give unsatisfactory yields and oily, dark byproducts, which were extremely difficult to remove even by column chromatography. Therefore

25 excessive amine was used as a hydrogen acceptor instead of triethylamine. To a

solution of the required triaryl chloride (5 mmol) in anhydrous acetonitrile (100 ml) was added an excess of the required amine (10-20 mmol). After stirring under reflux for 8 h the mixture was poured into cold water (400 ml) and kept at 4 °C for 2 h. The precipitate formed was collected by vacuum filtration, thoroughly washed with water to remove any of the remaining amine, and recrystallized from ethanol.

Example 10

Preparation of 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (Compound

10 T34)

1.50 g (4.8 mmol) of 2-chlorotriyl chloride obtained under Example 5 was reacted with 1.00 g (15 mmol) of pyrazole according to general method D to give 1.26 g (76%) of 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole, mp: 135 °C.

15

Example 11

Following the procedure in Example 9, the following compounds (Table 3) were prepared.

Table 3

Triaryl methylamines from Heterocyclic Amines	Designation on Appendix A	Yield	Melting Point
1-Trityl-1H-pyrazole	T11	82%	202 °C
1-[(4-Chlorophenyl)diphenylmethyl]-1H-pyrazole	T13	87%	133 °C
1-[Tris(4-methoxyphenyl)methyl]-1H-pyrazole	T19	82%	158 °C
1-[(4-Fluorophenyl)diphenylmethyl]-1H-pyrazole	T28	84%	145 °C
1-[Diphenyl(2-thienyl)methyl]-1H-imidazole	T37	78%	176 °C
1-[Diphenyl(2-thienyl)methyl]-1H-pyrazole	T38	83%	157 °C
1-[(2-Fluorophenyl)diphenylmethyl]-1H-pyrazole	T46	84%	192 °C
N-(1,3-thiazol-2-yl)-N-tritylamine	T57	79%	213 °C
1-{Diphenyl[2-(trifluoromethyl)phenyl]methyl}-1H-pyrazole	T58	46%	114 °C
1-{Diphenyl[2-(trifluoromethyl)phenyl]methyl}-3-(trifluoromethyl)-1H-pyrazole	T59	62%	107 °C
1-{Diphenyl[4-(trifluoromethyl)phenyl]methyl}-1H-pyrazole	T60	65%	135 °C
N-Diphenyl[4-(trifluoromethyl)phenyl]methyl-N-(1,3-thiazol-2-yl)amine	T61	58%	166 °C
1-[(2-Chlorophenyl)diphenylmethyl]-3,5-dimethyl-1H-pyrazole	T62	68%	195 °C
1-[(2-Chlorophenyl)diphenylmethyl]-3-methyl-1H-	T63	78%	118 °C

pyrazole			
<i>N</i> -[(4-Chlorophenyl)diphenylmethyl]- <i>N</i> -(1,3-thiazol-2yl)amine	T64	62%	156 °C
1-[(2-Chlorophenyl)diphenylmethyl]-3-(trifluoromethyl)-1 <i>H</i> -pyrazole	T65	64%	139 °C
<i>N</i> -[(2-Chlorophenyl)diphenylmethyl]- <i>N</i> -(1,3-thiazol-2yl)amine	T66	72%	152 °C
<i>N</i> -[(2-Chlorophenyl)diphenylmethyl]- <i>N</i> -(4-pyridyl)amine	T67	92%	115 °C
<i>N</i> -[(2-Chlorophenyl)diphenylmethyl]- <i>N</i> -(2-pyrimidyl)amine	T68	64%	162 °C
<i>N</i> -[(2-Chlorophenyl)diphenylmethyl]- <i>N</i> -(2-pyridyl)amine	T69	67%	115 °C
<i>N</i> -[(4-Chlorophenyl)diphenylmethyl]- <i>N</i> -(4-pyridyl)amine	T70	81%	214 °C
2-[(2-Chlorophenyl)diphenylmethyl]-1 <i>H</i> -isoindole-1,3(2 <i>H</i>)-dione	T71	67%	168 °C
<i>N</i> -Diphenyl[2-(trifluoromethyl)phenyl]methyl- <i>N</i> -(1,3-thiazol-2yl)amine	T72	65%	164 °C
<i>N</i> -Diphenyl[2-(trifluoromethyl)phenyl]methyl- <i>N</i> -(2-pyrimidinyl)amine	T73	78%	133 °C
<i>N</i> -[(2-Fluorophenyl)diphenylmethyl]- <i>N</i> -(1,3-thiazol-2yl)amine	T78	58%	169 °C
<i>N</i> -[(2-Chlorophenyl)diphenylmethyl]- <i>N</i> -(4-methyl-1,3-thiazol-2yl)amine	T79	49%	168 °C
<i>N</i> -{5-[(4-Nitrophenyl)sulfonyl]-1,3-thiazol-2yl}- <i>N</i> [(2-chlorophenyl)(diphenyl)methyl]amine	T81	73%	135 °C
1-[(2-Chlorophenyl)diphenylmethyl]-1 <i>H</i> -1,2,3,4-tetrazole	T84	72%	129 °C
1-[(2-Chlorophenyl)diphenylmethyl]-1 <i>H</i> -1,3-benzimidazole	T85	68%	168 °C

Example 12

Preparation of *N,N*-1,2-Ditritylamino ethane (Compound T21)

- 5 2.0 g (7.2 mmol) of trityl chloride, 0.21 g (3.6 mmol) of 1,2-diaminoethane and 0.72 g (7.2 mmol) of triethyl amine were dissolved in methylene chloride and heated under reflux for 8 hours as described under Example 6 (Ng 1995, *Tetrahedron* 51: 7883) to yield 1.03 g (53%) of *N,N*-1,2-ditritylamino ethane, mp: 172 °C

10

Example 13

The procedure in Example 12 was followed to obtain the following compounds (Table 4).

Table 4

Bis-triarylmethyldiamines from Diamines	Number	Yield	Melting Point
N,N-1,3-Ditritylamino propane	T22	58%	179 °C
1,4-Ditritylaminomethyl benzene	T23	64%	201 °C
N,N-1,2-[(2-Chlorophenyl)diphenylmethyl]amino ethane	T48	62%	228 °C
N,N-1,3-[(2-Chlorophenyl)diphenylmethyl]amino propane	T49	58%	198 °C

5

Example 14**Preparation of (2-chlorophenyl)diphenylmethyl amine (Compound T41)**

To a solution of 1.50 g (4.79 mmol) of (2-Chlorophenyl) diphenyl
 10 chloromethane, obtained under Example 5, in 100 ml of ethyl ether was added
 100 ml of 25% ammonia solution and the resulting mixture was vigorously stirred
 at room temperature for 24 hours (Casadio 1973, *J. Pharm. Sci.* 62: 773). The
 organic layer was separated and the aqueous layer was extracted with ether.
 The combined organic phases were thoroughly washed with water, dried over
 15 anhydrous sodium sulfate and evaporated to dryness. The oily residue was
 crystallized from petroleum ether (40-60 °C) to give 1.10 g (78%) of the product,
 mp: 98 °C.

Example 15

20 Following the procedure set forth in Example 14, the following three
 compounds were prepared (Table 5).

Table 5

Triarylmethylamines from Ammonia	Number	Yield	Melting Point
(4-Fluorophenyl)diphenylmethyl amine	T42	81%	62 °C
(2-Fluorophenyl)diphenylmethyl amine	T47	79%	84 °C
(2-Trifluoromethylphenyl)diphenylmethyl amine	T82	62%	106 °C

Example 16**Preparation of N-(2-chlorophenyl)diphenylmethyl acetamide (T75)**

5 2.5 g (8.51 mmol) of (2-chlorophenyl) diphenylmethyl amine obtained under Example 14 was acetylated with 30 ml of freshly distilled acetic anhydride. The resulting mixture was stirred at 40 °C for 4 hours , poured into 200 ml of cold water and left in the refrigerator overnight. The precipitate was collected by vacuum filtration and recrystallized from ethanol to yield 1.17 g (41%) of the
10 product, mp: 181 °C.

Example 17

Following the procedure in Example 16 the following N-triarylmethyl acetamides were prepared from the corresponding amines obtained under
15 Example 15 (Table 6).

Table 6

N-Triarylmethylacetamides from corresponding Amines	Number	Yield	Melting Point
N-(2-Fluorophenyl)diphenylmethyl acetamide	T76	73%	215 °C
N-(2-Trifluoromethylphenyl)diphenylmethyl acetamide	T83	83%	185 °C

20

Example 18**Preparation of 2-(4-Chlorophenyl)-2,2-diphenylacetonitrile (T26)**

2-(4-Chlorophenyl) 2,2-diphenylacetonitrile was synthesized by carefully triturating 1.50 g (4.8 mmol) of 4-chlorotriptyl chloride with 1.00 g (11 mmol) of copper cyanide and the resulting mixture was heated for 4 hours at 150°C without
25 a solvent. After cooling 50 ml of toluene was added, the mixture was filtered and the filtrate was concentrated in vacuo. The resulting residue was recrystallized from petroleum ether (40-60 °C) to give 0.66 g (45%) of the triarylmethyl acetonitrile derivative.

Example 19

The following triarylmethyl acetonitriles were prepared by the procedure outlined in Example 18 (Table 7)

5

Table 7

Triarylmethylacetonitriles from corresponding Chlorides	Number	Yield	Melting Point
2-(4-Fluorophenyl) 2,2-diphenylacetonitrile	T27	52%	76 °C
2-(2-Chlorophenyl) 2,2-diphenylacetonitrile	T39	52%	143 °C
2-(2-Fluorophenyl) 2,2-diphenylacetonitrile	T40	63%	144 °C

Compounds T39 and T40 have been disclosed in Brugnara, PCT Application WO 97/34589. Compounds T50 (4-pyridyl,diphenyl methanol), T51 (2,2,2-Triphenyl propionic acid), T52 [(S)-(-)- α,α -diphenyl-2-pyrrolidine methanol] and T53 [(R)-(+)- α,α -diphenyl-2-pyrrolidine methanol] used in the biological testing are commercially available from Aldrich Chemical. Co., Milwaukee, WI 53201, USA.

The following example provides an exemplary, but not limiting, formulation, for administering the compounds of the invention to mammals. Any of the compounds described herein, or pharmaceutically acceptable salts or hydrates thereof, may be formulated as illustrated in the following example.

Example 20**20 Gelatin Capsules**

Acid-resistant coated hard gelatin capsules are prepared using the following ingredients:

Compound T34	100 mg / capsule
Starch dried	200 mg / capsule
Magnesium stearate	10 mg / capsule

The above ingredients are mixed and filled into acid-resistant coated hard gelatin capsules in 310 mg quantities.

Example 21

In Vitro Activity

The assays are generally applicable for demonstrating the in vitro activity of compounds of General Formula (I).

A) Block of *IKCa1*

This example demonstrates the ability of the exemplary compounds, to inhibit the cloned human *IKCa1* channel. The cloning of human *IKCa1* has been previously reported (Fanger 1999, *J. Biol. Chem.* **274**: 5746). COS-7 cells, maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% heat-inactivated fetal calf serum, 4 mM L-glutamine and 1 mM Na⁺ pyruvate, were transiently transfected with *hIKCa1*.

Electrophysiological experiments were carried out in the whole-cell configuration of the patch-clamp technique using an EPC-9 amplifier (HEKA Elektronik, Lambrecht Germany) interfaced to a computer running acquisition and analysis software (Pulse and Pulsfit; HEKA Elektronik). Pipettes were pulled from soft glass capillaries, coated with Sylgard (Dow-Corning, Midland, MI), and fire polished to resistances of 2.0–4.5 MΩ measured in the bath. COS-7 cells were trypsinized and plated on glass coverslips 3 h before measurement. For measurements of *IK_{Ca}* currents an internal pipette solution containing 145 mM K⁺ aspartate, 2 mM MgCl₂, 10 mM HEPES, 10 mM K₂EGTA and 8.5 mM CaCl₂ (rendering 1 μM of free Ca²⁺), adjusted to pH 7.2 with NaOH, with an osmolarity of 290–310 mosM was used. To prevent activation of the native chloride channels in COS-7 cells an aspartate Ringer solution was used as an external solution (160 mM Na⁺ aspartate, 4.5 mM KCl, 2 mM CaCl₂, 1 mM MgCl₂, 5 mM HEPES, adjusted to pH 7.4 with NaOH, with an osmolarity of 290–310 mosM). 200 ms voltage ramps from –120 mV to 40 mV every 10 s were used. The holding potential in all experiments was –80 mV. Series resistance compensation was not employed. The reduction of slope conductance at –80 mV was used to determine the *K_d*-value by fitting the values to the Hill equation with a Hill coefficient of unity.

The results of this assay are provided in TABLE 8, below.

TABLE 8: K_d values for block of *IKCa1* stably transfected into COS-7 cells

Compound Designation in Appendix A	K_d [nM]
T1	550
T2	530
T3	520 (\pm 30)
T4	No effect at 1 μ M
T5	No effect at 1 μ M
T7	30 000
T8	No effect at 10 μ M
T9	1500
T10	28 000
T11	2500 (\pm 400)
T12	700
T13	90 (\pm 10)
T14	800
T15	10000
T16	10000
T17	35 000
T18	40 000
T19	No effect at 1 μ M
T20	No effect at 1 μ M
T23	No effect at 1 μ M
T24	8000
T26	750
T27	800
T28	200
T29	15000
T30	10000
T31	8000
T34	20 (\pm 3)
T35	9000

T36	700
T37	1000
T38	1100 (± 100)
T39	60
T40	60
T41	5000
T42	5000
T43	750
T45	1000
T46	40 (± 5)
T47	2000
T48	30000
T49	32000
T54	700
T55	820
T56	650
T57	n.d.
T58	5000
T59	25 000 (± 3)
T60	1500 (± 0.3)
T61	35 000
T62	12 000
T63	1100 (± 0.3)
T64	20 000
T65	2000 (± 0.5)
T66	15 000
T67	30 000
T68	900
T69	28 000
T70	11 000
T71	No effect at 10 μ M
T72	25 000

T73	15 000
T74	600
T75	1200
T76	1200
T77	800
T78	12 000
T79	8000
T81	15 000
T82	2500
T83	1500
T84	45 (\pm 7)
T85	No effect at 1 μ M
T86	1500 (\pm 500)

B) Selectivity of clotrimazole and 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (T34) for *IKCa1* over other ion channels

5 1-[(2-Chlorophenyl)diphenylmethyl]-1H-pyrazole (T34) was judged to be the most potent compound of the exemplary compounds covered by General Formula (I) and was further investigated for its selectivity over a whole range of other ion channels. Clotrimazole, the imidazole currently under clinical investigation for the treatment of sickle cell disease and diarrhea was used as a control. 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (T34) was also
10 investigated for its ability to block native *IKCa1* currents in activated human T-lymphocytes and in the human colonic epithelial cell line T84.

L929 cells stably expressing *mKv1.1*, *rKv1.2*, *mKv1.3*, and *mKv3.1* and MEL cells stably expressing *hKv1.5* have been previously described (Grissmer
15 1994, *Mol. Pharmacol.* 45: 1227). *hKv1.4* and *rKv4.2* were stably expressed in LTK (HK1-7). Channel expression was induced 8-12 h before the electrophysiological experiments by 4 μ M dexamethasone (Sigma). HEK-293 cells stably expressing the skeletal muscle sodium channel *hSkM1* (SCN4A) were generated in the laboratory of Dr. F. Lehmann-Horn. HEK-293 cells stably
20 expressing *hSlo α* were obtained from Dr. Andrew Tinker (Center for Clinical

Pharmacology, University College London). L929, MEL, LTK and HEK cells were maintained in DMEM containing 10% heat-inactivated fetal calf serum (Summit Biotechnology, Fort Collins, CO) and 250 µg/ml G418 (Life Technologies, Inc.). Rat basophilic leukemia (RBL) cells were maintained in Eagle's minimum essential medium with 2mM L-glutamine and 10% fetal calf serum. CHO cell were maintained in F12K media (ATCC). Human leukemic Jurkat E6-1 cells were cultured in RPMI 1640 supplemented with 10% fetal calf serum and 1mM L-glutamine. T84 cells were maintained in a 1:1 mixture of Ham's F12 medium and DMEM with 2.5 mM L-glutamine and 10% fetal calf serum.

Human peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood samples of healthy volunteers using a lymphocyte separation medium (Accuspin System-Histopaque-1077, Sigma Diagnostics) and maintained in RPMI 1640 supplemented with 10% fetal calf serum, 1 mM L-glutamine, 1 mM Na pyruvate, 1% non essential amino acids. Purified T-lymphocytes were prepared by passage through a nylon wool column. Activated T cell blasts were prepared by treating the resting cells with 1 µg/ml phytohemagglutinin (PHA-P, DIFCO, Detroit, MI).

Recordings from the Jurkat SK_{Ca} channel were made in K⁺ aspartate Ringer. (Na⁺ was replaced by K⁺) with the same internal pipette solution. Recordings from the RBL inward rectifier (*rKir2.1*) were made in aspartate Ringer with a K⁺ aspartate based pipette solution containing 50 nM of free Ca⁺⁺. No ATP was added to the pipette solution, because within 15 min of recording we witnessed no significant channel rundown. For both SK_{Ca} and inward rectifier currents the reduction of slope conductance at -110 mV from 200 ms voltage ramps from -120 mV to 40 mV every 10 s was taken as a measure of channel block. BK_{Ca} currents were elicited by 200 ms voltage ramps from -80 to 80 mV every 30 s. In aspartate Ringer with 1 µM of free Ca⁺⁺ in the pipette solution currents turned on at -20 mV and the reduction of slope conductance at 35 mV was used to evaluate channel block. For measurements of Kv currents cells were bathed in normal Ringer solution (160 mM NaCl, 4.5 mM KCl, 2mM CaCl₂, 1 mM MgCl₂, 10 mM HEPES) and an internal pipette solution containing 134 mM KF, 2 mM MgCl₂, 10 mM HEPES, 10 mM EGTA, adjusted to pH 7.2 with NaOH, with an osmolarity of 290-310 mosM, was used. For recordings from Kv1.1, Kv1.3, Kv1.4,

Kv1.5, *Kv3.1* and *Kv4.2* the voltage was stepped to 40 mV from the holding potential for 200 ms every 30 s. K_d -values were determined by fitting the Hill equation to the reduction of peak current. For *Kv1.2*, because of its "use-dependent" activation, a different pulse protocol was used: 300 ms every 10 sec, and the reduction of the mean of the current between 80-100% of the pulse duration was fitted to the Hill equation. For sodium channel recordings we employed voltage steps to -15 mV every 10 sec. Series resistance compensation (60-80%) was used if currents exceeded 1 nA. Capacitative and leak currents were subtracted using the P/8 procedure. Whole-cell recordings of monovalent currents through Jurkat CRAC channels with Na^+ as the charge carrier were made as previously described (Kerschbaum 1999, *Science* 283: 836). For measurements of swelling-activated mini chloride currents (Ross 1994, *Biophys. J.* 66: 169) 3 days activated human T-lymphocytes were bathed in normal Ringer solution (290 mosM) and a hypertonic internal pipette solution containing 160 mM Cs glutamate, 2 mM MgCl_2 , 10 mM HEPES, 0.1 mM CaCl_2 , 1.1 mM EGTA, 4 mM Na_2ATP and 100 mM sucrose, adjusted to pH 7.2 with CsOH, with an osmolarity of 420 mosM, was used. Chloride currents were elicited by the same voltage ramps as IK_{Ca} currents and blocking potency of the compounds on the slope conduction at -40 mV was evaluated between 300 and 900 s after break-in. A simple syringe-driven perfusion system was used to exchange the bath solution in the recording chamber.

The results of this assay are provided in TABLE 9, below. The effect of 100 nM of 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T-34 in Appendix A) on cloned and native IK_{Ca1} currents is shown in FIGURE 1. As shown in TABLE 9 and FIGURES 1a-1c, 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T34) is a highly potent and selective blocker of both cloned and native IK_{Ca1} currents. Contrary to Clotrimazole, 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T34) does not inhibit the activity of CYP3A4, the major xenobiotic metabolizing enzyme of human liver (see TABLE 9).

TABLE 9

	Channel	Clotrimazole [nM]	T34 [nM]
IK _{Ca}	<i>HIKCa1</i>	70 ± 10 (n = 9)	20 ± 3 (n = 15)
	lymphocyte IK	100	25 ± 5 (n = 9)
	T84 IK	90 ± 15 (n = 9)	22 ± 10 (n = 9)
K	<i>mKv1.1</i>	10 000 ± 850 (n = 9)	9500 ± 1000 (n = 9)
	<i>rKv1.2</i>	5000 ± 730 (n = 9)	4500 ± 520 (n = 9)
	<i>mKv1.3</i>	6000 ± 440 (n = 9)	5000 ± 350 (n = 9)
	<i>hKv1.4</i>	6000 ± 520 (n = 9)	7500 ± 410 (n = 9)
	<i>hKv1.5</i>	8000 ± 890 (n = 9)	7000 ± 620 (n = 9)
	<i>mKv3.1</i>	33 000 ± 4000 (n = 9)	30 000 ± 5000 (n = 9)
	<i>rKv4.2</i>	8000 ± 950 (n = 9)	6000 ± 870 (n = 9)
	Jurkat-SK	22 000 ± 1200 (n = 6)	23 000 ± 2000 (n = 6)
	BK (<i>hSloα</i>)	24 000 ± 2000 (n = 9)	25 000 ± 1800 (n = 9)
	<i>rKir2.1</i>	no effect at 10 μM (n =	no effect at 10 μM (n = 3)
Na	<i>HSKM1</i>	7000 ± 550 (n = 9)	8000 ± 600 (n = 9)
Ca	Jurkat-CRAC	no effect at 10 μM (n =	no effect at 10 μM (n = 2)
Cl	Lymphocyte swelling-	not done	10 000 ± 3000 (n = 4)
	activated		
	COS-7	no effect at 10 μM (n =	no effect at 10 μM (n = 5)
	EC ₅₀ for inhibition	30	No inhibitory
	of CYP3A4	(99% inhibition at 100	effect at 10 μM (n = 2)

5 **C) Inhibition of cytochrome P450 3A4 catalytic activities by a single concentration of 10 test substances**

The test substances shown in Table 8 were evaluated for their inhibitory effect on the catalytic activity of human cytochrome P450 enzyme. Cytochrome

10 P450 3A4 (CYP3A4) is involved in many drug-drug interactions and in many other pathways in the body including the catabolism of steroids and xenobiotics. Inhibition of this enzyme was measured in 96 well plates with 7-benzyloxy-4-trifluoro-methylcoumarin (BFC) as the substrate and cDNA-derived enzymes in microsomes prepared from baculovirus-infected insect cells.

15 The inhibition study consisted of the determination of inhibition by the test substance on CYP3A4 catalytic activity. A single concentration of each model substrate (approximately the apparent K_m) and one test substance concentration (10 μM), were tested in duplicate. The compounds were prepared as 10 mM stock solutions in acetonitrile. Metabolism of the model substrate was assayed by

the production of 7-hydroxy-4-trifluoromethylcoumarin metabolite. The metabolite was detected by fluorescence.

Table 10 below provides a list of the name of enzymes examined, the catalog number of the microsomes used as a source of the enzyme, the concentration of the model substrate used, the amount of enzyme used, the final buffer concentration, and the positive control compound.

Table 10

Enzyme	CYP3A4
Catalog Number	P202
Substrate	BFC
Substrate Concentration	50 μ M
Pmole Enzyme per Well	1-2
Potassium Phosphate Buffer Concentration	200 mM
Positive Control (Concentration)	ketoconazole (5 μ M)

Assays were conducted in 96 well microtiter plates. The BFC substrate was initially prepared in acetonitrile. The final concentration of the substrate was 50 μ M, which is below the apparent K_m . Six wells were used for one test. Wells 1 and 2 contained a 10 μ M concentration of the test substance (except clotrimazole, which had 0.1 μ M), and wells 3 and 4 contained no test substance and wells 5 and 6 were blanks for background fluorescence (stop solution added before the enzyme). For the positive controls, 12 wells in a row were used for one test. The positive control inhibitor/enzyme combination was examined in duplicate rows. Wells 1 to 8 contained serial 1:3 dilutions of the inhibitors. The highest inhibitor concentration were as described in the table above. Wells 9 and 10 contained no inhibitor and wells 11 and 12 were blanks for background fluorescence (stop solution added before the enzyme).

After buffer, cofactors and inhibitor addition, the plates were pre-warmed to 37°C. Incubations were initiated by the addition of pre-warmed enzyme and substrate. The final cofactor concentrations were 1.3 mM NADP, 3.3 mM glucose-6-phosphate and 0.4 U/ml glucose-6-phosphate dehydrogenase. The final incubation volume was 0.2 ml. Incubations were carried out for 30 minutes

[CYP3A4 (BFC)] and stopped by the addition of 0.075 ml of 80% acetonitrile-20% 0.5M Tris. Fluorescence per well was measured using a BMG FLUOstar fluorescence plate reader. The BFC metabolite 7-hydroxy-4-trifluoromethyl-coumarin was measured using an excitation wavelength of 410 nm and emission wavelength of 538 nm.

All results listed in Table 11 are consistent with a properly functioning model with 0.1 μ M of clotrimazole producing 99% of inhibition. The ambivalent effects (e.g. inhibition or activation) on CYP3A4 catalytic activity by some compounds is commonly observed with CYP3A4. One explanation for this is that the enzyme is capable of accommodating 2 or more compounds simultaneously, one of which may activate, or inhibit metabolism of the other (Thummel 1998, *Ann. Rev. Pharmacol. Toxicol.* 38: 389). Although activation of CYP3A4 enzymatic activity is commonly observed *in vitro*, to our knowledge, this has not been demonstrated *in vivo* in humans. It appears that the compounds designated as T3, T34, T58 and T75 on Appendix A have the potential for activation metabolism of compounds that are substrates for CYP3A4.

TABLE 11 Percent of inhibition of catalytic activity of CY3A4

Test compound	concentration	% inhibition
T3	10 μ M	-30.5
T34	10 μ M	-77.5
T39	10 μ M	10
T40	10 μ M	9
T58	10 μ M	-26
T66	10 μ M	86.5
T67	10 μ M	74
T74	10 μ M	4
T75	10 μ M	-54
clotrimazole	0.1 μ M	99

D) *In vitro* toxicity

The *in vitro* toxicity was performed as follows. Jurkat E6-1, MEL, C₂F₃, NGP, NLF cells and human T-lymphocytes were seeded at 5x10⁵ cells/ml, and
 5 L929, COS-7, CHO and RBL cells were seeded at 10⁵ cells/ml in twelve-well plates. Drug (2 or 5 µM) was added in a final DMSO concentration of 0.1%. After 48 h of incubation at 37 °C with 5% CO₂, cells were harvested by sucking them off the plates (suspension cells) or by trypsinization (adherent cell lines). Cells were centrifuged, resuspended in 0.5 ml PBS containing 1 µg/ml propidium
 10 iodide (PI), and red fluorescence measured on a FACScan flow cytometer after 20 min, 10⁴ cells of every sample being analyzed. The percentage of dead cells was determined by their PI uptake. Two controls for every cell line (one in medium and one with 0.1% DMSO) were also analyzed.

The results of this *in vitro* toxicity assay are shown in TABLE 12. 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole (T34 in Appendix A), at a
 15 concentration 100-250 times the K_d for IKCa1 channel block, did not reduce cell viability in any of the ten cell lines examined.

TABLE 12

Cells *	Control	control 0.1% DMSO	2 µM T34	5 µM T34
T-lymphocytes	6.1	7.1	6.2	7.0
Jurkat E6-1	3.2	2.3	2.5	3.2
MEL	5.1	4.8	6.2	5.8
L929	9.6	7.8	4.6	7.5
COS-7	4.5	4.0	3.6	4.5
CHO	4.6	5.6	5.6	4.7
RBL-2H3	5.5	7.6	7.9	8.8
C ₂ F ₃	17.4	14.3	15.8	12.8
NLF	12.8	9.1	10.8	10.8
NGP	8.0	4.2	10.9	5.9

20

* MEL, murine erythroleukemia cells; L929, murine fibrosarcoma cell; COS-7, SV40 transformed African green monkey kidney; CHO, Chinese hamster ovary

cells; RBL-2H3, rat basophilic leukemia cells; Jurkat E6-1, human leukemic T-cell line; C₂F₃ human myoblasts; NGP and NLF human neuroblastoma cell lines.

E) Acute *in vivo* toxicity

- 5 An ISO acute systemic toxicity study was performed in CF-1 BR mice (17-19 g) according to the guidelines of the *United States Pharmacopeia* XXII. Five mice were injected intravenously with a single 0.9-1.0 ml (50 ml/kg) dose of 0.5 mg/kg 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T34) (29 µM in mammalian Ringer solution with 1% ethanol and 2.5% bovine serum albumin).
- 10 Mice were observed for adverse effects immediately after dosing, at 4 h after injection and daily for 7 days. Five control mice were injected with an equal volume of the vehicle. The mice were weighed at the beginning of the study and at its termination.

- The results clearly showed that there was no mortality and all animals
- 15 appeared clinically normal during the 7-day study. The body weight data of the test compound treated group (wt on day 1: 17.8 g; wt on day 7: 27.0 g) were similar to controls (day 1: 17.4 g; day 7: 23.4 g) during the study. These data, taken together with the data from the cell viability assay, suggest that 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T34) was not toxic at ~100-1000
- 20 times the pharmacological dose thus exhibiting a very good therapeutic index.

F) Hydrolytic stability of 1-[(2-Chlorophenyl)diphenylmethyl]-1*H*-pyrazole (T34) vs. Clotrimazole

- Applicants investigated the stability of 1-[(2-chlorophenyl)diphenylmethyl]-
- 25 1*H*-pyrazole (T34 in Appendix A) against hydrolysis at pH 7.4 and at pH 5.0. The resulting concentrations of compound T34 and its expected degradation product (2-chlorophenyl)diphenyl methanol (T3) in analogy to clotrimazole were determined by HPLC.

- To access oral bioavailability the stability of 1-[(2-chlorophenyl)diphenyl
- 30 methyl]-1*H*-pyrazole (T34 in Appendix A) under acidic conditions was determined at pH 1 in artificial stomach fluid (DAB9).

A Waters 590 liquid chromatograph with a Waters 746 integrator and a Waters 486 UV/Vis detector, and a 25 cm Lichrospher RP18 column (5-µM

particle size) was used. The mobile phase consisted of K_2HPO_4 25 mM, KH_2PO_4 30 mM, methanol at 262 : 13 : 725. The chromatographic separation was performed at 20 °C with a flow rate of 1.0 ml/min, the absorbance of the elluent was monitored at 210 nm.

5 Hydrolysis profiles (10 μ M compound with 20% acetonitrile) were carried out in Soerensen phosphate buffer (pH 7.4 and pH 5.0) in a total volume of 10 ml. 100 μ l samples were collected 0, 1, 2, 3, 4, 5, 24, 48 and 72 hours after incubation, with shaking, in a waterbath at 37 °C and manually injected into the HPLC over Rheodyne 7125 system. For profiles at pH 1.0 artificial stomach fluid
10 (DAB 9), containing 2g NaCl, 3,2g pepsin and 80ml 1M HCL in 1.0 L of water was used. After 0, 1 and 2 hours 400 μ l of sample were collected and extracted three times with 500 μ l of ethyl ether by vortexing. The combined extracts were than evaporated to dryness by passing nitrogen through the solution. The residue was than dissolved in 400 μ l of mobile phase of which 100 μ M were injected in the
15 HPLC. The recovery rate from this extraction procedure was 80%.

This chromatographic system gave retention times of 16.1 min for T3, 20.6 min for clotrimazole and 23.4 min for T34. Whereas clotrimazole slowly hydrolyzed at pH 5.0 (22% T3 after 48 h, 35 % T3 after 72 h), T34 was completely stable against hydrolysis at pH 7.4 and pH 5.0 over 72 h (see FIGURE 2).

20 As shown in FIGURE 2, the results clearly show that compound T34 was completely stable against hydrolysis at pH 10, pH 7.4 and pH 5.0 over 72 h (pH 10.0 is not shown). Specifically, FIGURE 2 shows the hydrolysis of compound T34 and clotrimazole at pH 7.4 and pH 5.0 (for clotrimazole at pH 5.0 the corresponding amount of T3 can be detected at the corresponding retention time
25 (mean of 3 determinations). At pH 1.0 T34 rapidly breaks down to T3 with a half-life of ~45 min (FIGURE 3).


These results demonstrate that T34 can be used in T-lymphocyte proliferation and cytokine secretion assays. However, for oral administration T34 should be used in an acid-resistant coated formulation.

30 The compounds of this invention, or pharmaceutically acceptable salts or hydrates thereof, can be delivered to a patient using a wide variety of routes or modes of administration. Suitable routes of administration include, but are not limited to, inhalation, transdermal, oral, rectal, transmucosal, intestinal and


parenteral administration, including intramuscular, subcutaneous and intravenous injections. The compounds described herein, or pharmaceutically acceptable salts or hydrates thereof, may be administered singly or in combination with other therapeutic agents, e.g. analgesics, antibiotics and other immunosuppressive drugs like cyclosporin A or Kv1.3 selective blockers. The active compound (T34) may be administered *per se* or in the form of a pharmaceutical composition wherein the active compound is in admixture with one or more physiologically acceptable carriers, excipients or diluents. Pharmaceutical compositions for use in accordance with the present invention may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is dependent on the route of administration chosen. For parenteral administration (bolus injection or continuous infusion), the agents of the invention may be formulated in water soluble form in aqueous solutions, preferably in physiologically compatible buffers such as Hank's solution, Ringer's solution, or physiological saline buffer. Additionally, suspensions of the compounds may be prepared as oily injections with fatty oils, synthetic fatty acid esters, or liposomes. The compounds may also be formulated as a depot preparation. For oral administration, the compounds can be formulated readily by combining the active compound with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion for patients to be treated. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl-methylcellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone.

APPENDIX A


Exemplary Compounds




T1




T2




T3




T4




T5




T7




T8




T9




T10




T11




T12




T13




T14




T15




T16




T17




T18




T19




T20




T21




T22




T23




T24




T26




T27




T28




T29




T30















T31




T32




T33


**T34****T35****T36****T37****T38****T39****T40****T41****T42****T43****T44****T45**




T46




T47




T48




T49




T50




T51




T52




T53















T54




T55




T56


**T57****T58****T59****T60****T61****T62****T63****T64****T65****T66****T67****T68**




T69




T70




T71




T72




T73




T74




T75




T76









T77



T78



T79


**T81****T82****T83****T84****T85****T86**

The compounds will be referred to herein by their compound numbers as given above.

CLAIMS

5 We claim:

1. A method for treating or preventing an autoimmune disorder, transplant rejection or graft-versus-host disease in a mammalian patient, said method comprising the step of administering to the patient a therapeutically effective
 10 amount of a compound having the formula:



Formula I

Wherein,

X, Y and Z are same or different and are independently selected from CH₂, O, S, NR₁, N=CH, CH=N and R₂-C=C-R₃, where R₂ and R₃ are H or may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups;

R₁ is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxycarbonyl groups;

R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy, alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxycarbonyl, N-(R₄)(R₅) and saturated or unsaturated, chiral or achiral, cyclic or acyclic, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms, optionally substituted with hydroxy, halogen,


trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxycarbonyl, oxoalkyl, cyano and N-(R₄)(R₅) group,

5 R₄ and R₅ are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R₄ and R₅ may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or N-R₆,

10 R₆ is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl,

n is 0-5; m is 1 or 2; with the proviso that when m is 1, Q is selected from OH, CN, carboxyalkyl, N-(R₇)(R₈), where R₇ and R₈ are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl, amido, or R₇ and R₈ may combine to form a saturated or unsaturated heterocyclic ring and optionally substituted with up to 3 additional heteroatoms selected from N, O, and S; or

20 -NH-heterocycle, where the heterocycle is represented by thiazole, oxazole, isoxazole, pyridine, pyrimidine, and purine and where U and V are selected from H and O; and



25 when m is 2, Q is a spacer of from 2-10 carbons either as a straight or branched, chiral or achiral, cyclic or acyclic, saturated or unsaturated, hydrocarbon group, such as phenyl.

30 In the most preferred embodiment of this invention, X, Y, and Z are R₂-C=C-R₃, where R₂ and R₃ are H; R is selected from H and halogen, preferably, F and Cl;

35 m is 1; and Q is -N-(R₇)(R₈), where R₇ and R₈ are selected from H, acyl, amido, and R₇ and R₈ combine to form a saturated or unsaturated heterocyclic ring, optionally substituted with up to three heteroatoms selected from N, O, or S, for example, pyrrolidine, piperidine, pyrazole, oxazole, isoxazole, tetrazole, azepine, etc., which may be optionally substituted with a lower alkyl or amino group.

2. A method according to Claim 1 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole.

3. A method according to Claim 1 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole.
- 5 4. A method according to Claim 1 wherein the compound is 1-[(4-chlorophenyl)diphenylmethyl]-1*H*-pyrazole.
5. A method according to Claim 1 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole.
- 10 6. A method according to Claim 1 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-1,2,3,4-tetrazole.
7. A method according to Claim 1 wherein the compound is 2-(2-chlorophenyl)-2,2-diphenylacetonitrile.
- 15 8. A method according to Claim 1 wherein the compound is 2-(2-fluorophenyl)-2,2-diphenylacetonitrile.
- 20 9. A method for therapeutic inhibition of calcium activated potassium channels encoded by *IKCa1* in a target cell type of a mammalian patient, without causing side effects due to concomitant inhibition of cytochrome P-450 enzyme activity, said method comprising the steps of:
 - 25 (A) selecting a substituted triaryl methane compound covered by Claim 1 that causes inhibition of calcium activated potassium channels encoded by *IKCa1* in the target cell type of animals of the same species as the mammalian patient but which does not cause inhibition of activity of any cytochrome P-450 enzymes in any tissue of animals of the same species of the mammalian patient at concentrations that are at least 50 times greater than the half-blocking concentration of that compound required for inhibition of said calcium activated potassium channels; and,
 - 30 (B) administering the substituted triaryl methane compound covered by Claim 1 and selected in Step A to the patient in an amount that

is effective to inhibit calcium activated potassium channels encoded by *IKCa1* in the patient's cells of the target cell type but which does not substantially inhibit activity of any cytochrome P-450 enzyme .

5

10. A method according to Claim 7 wherein the target cell type is selected from the group of target cell types consisting of :

- T-lymphocytes;
- B-lymphocytes
- 10 Macrophages
- Monocytes
- Platelets
- endothelial cells;
- cancer cells;

15

11. A method according to Claim 7 wherein the compound selected in Step A is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole.

12. A method according to Claim 7 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-pyrazole.

13. A method according to Claim 7 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole .

25 14. A method according to Claim 7 wherein the compound is 1-[(4-chlorophenyl)diphenylmethyl]-1*H*-pyrazole .

15. A method according to Claim 7 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole .

30

16. A method according to Claim 7 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-1,2,3,4-tetrazole.


17. A method according to Claim 7 wherein the compound is 2-(2-

chlororophenyl)-2,2-diphenylacetonitrile.

18. A method according to Claim 7 wherein the compound is 2-(2-fluorophenyl)-2,2-diphenylacetonitrile.

5

19. A method for suppressing antigen- or cytokine- or mitogen-stimulated calcium entry via store-operated calcium channels in lymphocytes, monocytes, macrophages, platelets and endothelial cells and/ or cytokine production by these cells and/or activation of these cells of a mammalian patient, without concomitant cytochrome P450 inhibition, said method comprising the step of administering to
- 10 the patient a therapeutically effective amount of a compound having the formula :



wherein;

- 15 X, Y and Z are the same or different and are independently selected from CH₂, O, S, NR₁, N=CH, CH=N and R₂-C=C-R₃, where R₂ and R₃ are H or may combine to form a saturated or unsaturated carbocyclic or heterocyclic ring, optionally substituted with one or more R groups;
- R₁ is selected from H, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, acyl and
- 20 aroyl, optionally substituted with hydroxy, amino, substituted amino, cyano, alkoxy, halogen, trihaloalkyl, nitro, thio, alkylthio, carboxy and alkoxy carbonyl groups;

- R is selected from H, halogen, trihaloalkyl, hydroxy, acyloxy, alkoxy,
- 25 alkenyloxy, thio, alkylthio, nitro, cyano, ureido, acyl, carboxy, alkoxy carbonyl, N-(R₄)(R₅) and saturated or unsaturated, chiral or achiral,

cyclic or acyclic, straight or branched hydrocarbyl group with from 1 to 20 carbon atoms, optionally substituted with hydroxy, halogen, trihaloalkyl, alkylthio, alkoxy, carboxy, alkoxycarbonyl, oxoalkyl, cyano and N-(R₄)(R₅) group,

5

R₄ and R₅ are selected from H, alkyl, alkenyl, alkynyl, cycloalkyl and acyl or R₄ and R₅ may combine to form a ring, wherein a carbon may be optionally substituted by a heteroatom selected from O, S or N-R₆,

10

R₆ is H, alkyl, alkenyl, alkynyl, cycloalkyl, hydroxyalkyl or carboxyalkyl,

n is 0-5; m is 1 or 2; with the proviso that

when m is 1, Q is selected from OH, CN, carboxyalkyl, N-(R₇)(R₈), where

R₇ and R₈ are selected from H, lower alkyl (1-4C), cycloalkyl, aryl, acyl,

15


amido, or R₇ and R₈ may combine to form a saturated or unsaturated

heterocyclic ring and optionally substituted with up to 3 additional

heteroatoms selected from N, O, and S; or

-NH-heterocycle, where the heterocycle is represented by thiazole,

oxazole, isoxazole, pyridine, pyrimidine, and purine and



20

where U and V are selected from H and O; and

when m is 2, Q is a spacer of from 2-10 carbons either as a straight or branched, chiral or achiral, cyclic or acyclic, saturated or unsaturated,

25

hydrocarbon group such as phenyl.

20. A method according to Claim 19 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole.

21. A method according to Claim 19 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole.
22. A method according to Claim 19 wherein the compound is 1-[(4-chlorophenyl)diphenylmethyl]-1*H*-pyrazole.
23. A method according to Claim 19 wherein the compound is 1-[(2-fluorophenyl)diphenylmethyl]-1*H*-pyrazole .
24. A method according to Claim 19 wherein the compound is 1-[(2-chlorophenyl)diphenylmethyl]-1*H*-1,2,3,4-tetrazole.
25. A method according to Claim 19 wherein the compound is 2-(2-chlorophenyl)-2,2-diphenylacetonitrile
26. A method according to Claim 19 wherein the compound is 2-(2-fluorophenyl)-2,2-diphenylacetonitrile
27. A method according to Claim 1 wherein the method is carried out for the purpose of treating or preventing an autoimmune disorder, transplant rejection or graft-versus-host disease in a mammalian patient.
28. A method according to Claim 1 wherein the method is carried out for the purpose of causing immunomodulation.
29. A method according to Claim 28 wherein the method is carried out for the purpose of causing immunomodulation as a treatment for an autoimmune disorder, to prevent transplant rejection or to treat graft-versus-host disease.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 July 2001 (12.07.2001)

PCT

(10) International Publication Number
WO 01/49663 A3

- (51) International Patent Classification⁷: **A61K 31/415**, 31/425, 31/41, 31/40, 31/16
- (74) Agents: **BUYAN, Robert, D.** et al.: Stout, Uxa, Buyan & Mullins, LLP, 4 Venture #300, Irvine, CA 92618 (US).
- (21) International Application Number: **PCT/US01/00326**
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 5 January 2001 (05.01.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 09/479,391 6 January 2000 (06.01.2000) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; Office of Technology Transfer, 12th Floor, 1111 Franklin Street, Oakland, CA 94607-5200 (US).
- Published:
— with international search report
- (72) Inventors: **CHANDY, K., George**; 2118 Morningside Drive, Laguna Beach, CA 92651 (US). **WULFF, Heike**; 4109 Palo Verde Road, Irvine, CA 92612 (US). **CAHALAN, Michael, D.**; 2903 Mountain View Drive, Laguna Beach, CA 92651 (US). **GRISMER, Stephan**; Nelly Sachs Str. 4, 89134 Blaustein (DE). **RAUER, Heiko, J.**; 24 Gabrielino Drive, Irvine, CA 92612 (US). **MILLER, Mark, J.**; 127 Dalewood Place, Brea, CA 92821 (US).
- (88) Date of publication of the international search report:
7 February 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/49663 A3

(54) Title: **NON-PEPTIDE INHIBITION OF T-LYMPHOCYTE ACTIVATION AND THERAPIES RELATED THERETO**

(57) Abstract: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K⁺ channel (*IKCa1*) in Lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca⁺⁺ activated K⁺ channel (*IKCa1*) prevents the pre-Ca⁺⁺ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US01/00326

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/415, 31/425, 31/41, 31/40, 31/16
US CL : 514/403, 381, 394, 385, 365, 390, 408, 609

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/403, 381, 394, 385, 365, 390, 408, 609

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN: compounds and therapeutic methods, immunosuppression, cytochrome P-450 and T-cell

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Chemical Abstracts Service, (Columbus, Ohio, USA), 121:148547, AUSSEL et al, "Regulation of T cell activation by cytochrome P450 inhibitors." Cell. Immunol., Vol. 155(2), 1994, pages 436-445, see entire abstract.	1, 27-29
Y		1, 9-10, 19, 27-29
A	Chemical Abstracts Service, (Columbus, Ohio, USA), 133:202592, Wulff et al, "Design of a potent and selective inhibitor of the intermediate-conductance Ca ²⁺ -activated K ⁺ channel", Proc. Natl. Acad. Sci., Vol. 97(14), 2000, pages 8151-8156, see entire abstract.	1-29

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* "A"	Special categories of cited documents document defining the general state of the art which is not considered to be of particular relevance	*T Later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*E	earlier document published on or after the international filing date	*X document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*L	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Y document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*O	document referring to an oral disclosure, use, exhibition or other means	*G document member of the same patent family
*P	document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 JULY 2001

Date of mailing of the international search report

05 NOV 2001

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer


 RUSSELL TRAVERS

Telephone No. (703) 308-1235